EMD Serono, Inc. Launches 10th Edition of The EMD Serono Specialty Digest™ at Annual Meeting of The Academy of Managed Care Pharmacy
ROCKLAND, Mass., April 1, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the launch of the 10th edition of the EMD Serono Specialty Digest™ at the 26th Annual Meeting of The Academy of Managed Care Pharmacy (AMCP) in Tampa, FL. The Digest is an educational resource that provides market data on health plans' management of specialty pharmaceuticals in 2013 and identifies common trends occurring across plans. The Digest is available to those who request a copy at http://www.specialtydigest.emdserono.com.
The 10th edition of the EMD Serono Specialty Digest™ includes data from 91 health plans across the country, representing more than 124 million covered lives. This year's digest has been enhanced to reflect current opportunities, challenges and solutions to specialty drug management, including new utilization management practices, integration of pharmacy and medical benefits, strategies to address reimbursement issues across different sites of service and oncology management.
Findings from this year's EMD Serono Specialty Digest™ show that while specialty drugs continue to become the standard of care for many complex diseases, more health plans are utilizing a multi-tier cost share structure. Many plans have implemented a preferred and non-preferred formulary for specialty therapies. Additionally, health plan management of oncology drugs is an important area of increasing payer focus - 51% of the 91 surveyed plans have either implemented oncology pathways or expect to implement oncology pathways in the next 12 months.
"We are committed to partnering with our customers to build an understanding of trends in the management of specialty pharmaceuticals," said Allene Diaz, Senior Vice President, Managed Markets, EMD Serono. "The insights in this year's EMD Serono Specialty Digest will help create a dialogue around access to therapy and improving patient outcomes."
Since its inception in 2004, health plans, employers, specialty pharmacies and pharmaceutical companies have relied upon the EMD Serono Specialty Digest™ to identify current and future trends in the management of specialty pharmaceuticals. Findings are available in the full text of the EMD Serono Specialty Digest™, at http://www.specialtydigest.emdserono.com.
About EMD Serono, Inc.
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a specialized biopharmaceutical company dedicated to developing therapies with groundbreaking potential. The company has strong market positions in neurology, endocrinology and in reproductive health. In addition, EMD Serono has an enduring commitment to solve the unsolvable, with state-of-the-art science dedicated to developing new therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology. With a long-standing history of industry expertise and a dedication to shape the future of healthcare, the company's US footprint continues to grow, with approximately 1,000 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.
For more information, please visit www.emdserono.com.
About Merck KGaA, Darmstadt, Germany
Merck KGaA of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. Its subsidiaries in Canada and the United States operate under the umbrella brand EMD. Around 38,000 employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. The company generated total revenues of €11.1 billion in 2013 with its four divisions: Biopharmaceuticals, Consumer Health, Performance Materials and Life Science Tools. Merck KGaA of Darmstadt, Germany is the world's oldest pharmaceutical and chemical company – since 1668, the name has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day.
SOURCE EMD Serono, Inc.